News & Perspective

(CIDRAP News) – The National Institutes of Health (NIH) yesterday announced it has awarded contracts, which could total $150 million over 5 years, to four companies to develop broad-spectrum therapies that could help the nation respond to a bioterror attack or other public health emergency.

(CIDRAP News) – Xoma Ltd., a Berkeley, Calif., pharmaceutical company, recently announced that it received a $65 million multiyear federal contract to fund work on botulinum antitoxins, one of which it hopes to put through safety and efficacy tests starting in 2009.

(CIDRAP News) – Emergent BioSolutions Inc. recently announced it had secured two federal grants totaling $4.5 million for development of its botulism and next-generation anthrax vaccine candidates.

Emergent, maker of the nation's only licensed anthrax vaccine, announced the grants from the National Institute of Allergy and Infectious Diseases (NIAID) in a Jul 24 news release.

Editor's note: This story was revised shortly after publication to reflect corrections issued by the National Institute of Allergy and Infectious Diseases on May 10. The corrections pertain to the total monetary amount of the grants and to the project descriptions for XOMA (US) LLC and DVC Dynport LLC.

(CIDRAP News) – Federal health officials yesterday released a 37-page report that they say demonstrates "tremendous progress" in developing countermeasures for bioterrorism through federally funded research since early 2002.

(CIDRAP News) – The National Institute of Allergy and Infectious Diseases (NIAID) has released a 68-page report on its plan for expanding research on "Category A" bioterrorism agents: anthrax, smallpox, plague, tularemia, viral hemorrhagic fevers, and botulism.

(CIDRAP News) – The US Department of Health and Human Services (HHS) has announced seven new research grant programs to speed efforts to prevent, diagnose, and treat diseases related to bioterrorism.